Measurement of absorption in scattering media using objective laser speckle: application to blood oximetry

Multi-spectral imaging enables non-invasive sensing of chemical concentrations in biological tissue based on measurement of optical absorption, but invariably in the presence of high levels of scatter. Absorption is normally inferred from measurement of contrast of biological features, such as the vasculature, and so accuracy is degraded by the poorly characterized modulation-transfer function of the imaging optics and overlying tissue. We report how experimental characterization of the spectral variation of the tissue point-spread function and associated objective speckle pattern can be used to characterize the absorption spectrum and chromophore concentration, with a particular emphasis on determination of the ratio of oxygenated to deoxygenated hemoglobin within blood. Absorption measurements are determined purely by the geometry of the experiment, without degradation due to optical aberrations and associated light scatter. The technique offers enhanced and low-cost determination of in vitro or in vivo chromophore characterizations, including blood-gas analysis

Recovery and restoration potential of cold‐water corals: experience from a deep‐sea marine protected area

Cold-water corals (CWCs) are important species that provide habitat for other taxa but are sensitive to mechanical damage from bottom trawling. CWC conservation has been implemented in the form of marine protected areas (MPAs), but recovery from impact may be particularly slow in the deep-sea environment; consequently, the use of restoration techniques has been considered. To gain some insight into CWC recruitment and growth, in 2011 we deployed small seabed moorings in the Darwin Mounds MPA (~1,000 m water depth). This site hosts hundreds of CWC mounds, that had previously (until 2003) been impacted by deep-water trawling. In 2019, we carried out in situ visual surveys of these moorings and the surrounding seabed environment, then recovered two of the moorings. The mooring buoys, glass floats with plastic covers, were extensively colonized by a diverse epifauna that included the CWCs Desmophyllum pertusum and D. dianthus. The presence of coral recruits indicated that environmental conditions, and larval supply, remained favorable for the settlement and growth of CWCs within the MPA. Based on our observations, we consider four possible restoration methods, together with a “do-nothing” option, for the Darwin Mounds CWCs that have shown little, if any, natural recovery despite 16 years of protection. We conclude that seabed emplacement of high-relief artificial substrata is likely to be the most efficient and cost-efficient means of promoting enhanced recovery of the CWCs

Recovery and restoration potential of cold‐water corals: experience from a deep‐sea marine protected area

Cold-water corals (CWCs) are important species that provide habitat for other taxa but are sensitive to mechanical damage from bottom trawling. CWC conservation has been implemented in the form of marine protected areas (MPAs), but recovery from impact may be particularly slow in the deep-sea environment; consequently, the use of restoration techniques has been considered. To gain some insight into CWC recruitment and growth, in 2011 we deployed small seabed moorings in the Darwin Mounds MPA (~1,000 m water depth). This site hosts hundreds of CWC mounds, that had previously (until 2003) been impacted by deep-water trawling. In 2019, we carried out in situ visual surveys of these moorings and the surrounding seabed environment, then recovered two of the moorings. The mooring buoys, glass floats with plastic covers, were extensively colonized by a diverse epifauna that included the CWCs Desmophyllum pertusum and D. dianthus. The presence of coral recruits indicated that environmental conditions, and larval supply, remained favorable for the settlement and growth of CWCs within the MPA. Based on our observations, we consider four possible restoration methods, together with a “do-nothing” option, for the Darwin Mounds CWCs that have shown little, if any, natural recovery despite 16 years of protection. We conclude that seabed emplacement of high-relief artificial substrata is likely to be the most efficient and cost-efficient means of promoting enhanced recovery of the CWCs

Measurement of the neutron-induced fission cross section of Th 230 at the CERN n_TOF facility

The neutron-induced fission cross section of 230 Th has been measured at the neutron time-of-flight facility n_TOF located at CERN. The experiment was performed at the experimental area EAR-1 with a neutron flight path of 185 m, using Micromegas detectors for the detection of the fission fragments. The 230 Th(n, f ) cross section was determined relative to the 235 U(n, f ) one, covering the energy range from the fission threshold up to 400 MeV. The results from the present work are compared with existing cross-section datasets and the observed discrepancies are discussed and analyzed. Finally, using the code EMPIRE 3.2.3 a theoretical study, based on the statistical model, was performed leading to a satisfactory reproduction of the experimental results with the proper tuning of the respective parameters, while for incident neutron energy beyond 200 MeV the fission of 230 Th was described by Monte Carlo simulations.This project received funding from the Euratom “Support safe operation of nuclear systems” program 2014–2018 under Grant Agreement No. 847552 (SANDA) and by the funding agencies of the participating institutes. This research is imple- mented through the IKY scholarships program and cofinanced by the European Union (European Social Fund ’ESF) and Greek national funds through the action entitled “Reinforce- ment of Postdoctoral Researchers - 2nd call (MIS 5033021)”, in the framework of the Operational Programme “Human Resources Development Program, Education and Lifelong Learning” of the National Strategic Reference Framework.Article signat per 137 autors/es: V. Michalopoulou, A. Stamatopoulos, M. Diakaki, A. Tsinganis, R. Vlastou, M. Kokkoris, N. Patronis, Z. Eleme, D. Macina, L. Tassan-Got, N. Colonna, E. Chiaveri, A. Ventura, P. Schillebeeckx, J. Heyse, G. Sibbens, G. Alaerts, A. Borella, A. Moens, D. Vanleeuw, O. Aberle, V. Alcayne, S. Amaducci, J. Andrzejewski, L. Audouin, V. Babiano-Suarez, M. Bacak, M. Barbagallo, S. Bennett, E. Berthoumieux, J. Billowes, D. Bosnar, A. Brown, M. Busso, M. Caamaño, L. Caballero, F. Calviño, M. Calviani, D. Cano-Ott, A. Casanovas, F. Cerutti, G. Cortés, M. A. Cortés-Giraldo, L. Cosentino, S. Cristallo, L. A. Damone, P. J. Davies, M. Dietz, C. Domingo-Pardo, R. Dressler, Q. Ducasse, E. Dupont, I. Durán, B. Fernández-Domínguez, A. Ferrari, P. Finocchiaro, V. Furman, K. Göbel, R. Garg, A. Gawlik-Ramiega, S. Gilardoni, I. F. Gonçalves, E. González-Romero, C. Guerrero, F. Gunsing, H. Harada, S. Heinitz, D. G. Jenkins, A. Junghans, F. Käppeler, Y. Kadi, A. Kimura, I. Knapová, Y. Kopatch, M. Krticka, D. Kurtulgil, I. Ladarescu, C. Lederer-Woods, H. Leeb, J. Lerendegui-Marco, S. J. Lonsdale, A. Manna, T. Martínez, A. Masi, C. Massimi, P. Mastinu, M. Mastromarco, E. A. Maugeri, A. Mazzone, E. Mendoza, A. Mengoni, P. M. Milazzo, F. Mingrone, J. Moreno-Soto, A. Musumarra, A. Negret, R. Nolte, F. Ogállar, A. Oprea, A. Pavlik, J. Perkowski, C. Petrone, L. Piersanti, E. Pirovano, I. Porras, J. Praena, J. M. Quesada, D. Ramos-Doval, T. Rauscher, R. Reifarth, D. Rochman, Y. Romanets, C. Rubbia, M. Sabaté-Gilarte, A. Saxena, D. Schumann, A. Sekhar, A. G. Smith, N. V. Sosnin, P. Sprung, G. Tagliente, J. L. Tain, A. Tarifeño-Saldivia, Th. Thomas, P. Torres-Sánchez, J. Ulrich, S. Urlass, S. Valenta, G. Vannini, V. Variale, P. Vaz, D. Vescovi, V. Vlachoudis, A. Wallner, P. J. Woods, T. Wright, and P. Žugec.Postprint (published version

Neutron-induced fission cross sections of Th 232 and U 233 up to 1 GeV using parallel plate avalanche counters at the CERN n_TOF facility

The neutron-induced fission cross sections of 232 Th and 233 U were measured relative to 235 U in a wide neutron energy range up to 1 GeV (and from fission threshold in the case of 232 Th , and from 0.7 eV in case of 233 U ), using the white-spectrum neutron source at the CERN Neutron Time-of-Flight (n_TOF) facility. Parallel plate avalanche counters (PPACs) were used, installed at the Experimental Area 1 (EAR1), which is located at 185 m from the neutron spallation target. The anisotropic emission of fission fragments were taken into account in the detection efficiency by using, in the case of 233 U , previous results available in EXFOR, whereas in the case of 232 Th these data were obtained from our measurement, using PPACs and targets tilted 45 ° with respect to the neutron beam direction. Finally, the obtained results are compared with past measurements and major evaluated nuclear data libraries. Calculations using the high-energy reaction models INCL + + and ABLA07 were performed and some of their parameters were modified to reproduce the experimental results. At high energies, where no other neutron data exist, our results are compared with experimental data on proton-induced fission. Moreover, the dependence of the fission cross section at 1 GeV with the fissility parameter of the target nucleus is studied by combining those ( p , f ) data with our ( n , f ) data on 232 Th and 233 U and on other isotopes studied earlier at n_TOF using the same experimental setup.Peer ReviewedArticle escrit per 81 autors/autores: D. Tarrío , L. Tassan-Got, I. Duran, L. S. Leong, C. Paradela, L. Audouin, E. Leal-Cidoncha, C. Le Naour, M. Caamaño, A. Ventura, S. Altstadt, J. Andrzejewski, M. Barbagallo, V. Bécares, F. Becvá ˇ ˇr,F. Belloni, E. Berthoumieux, J. Billowes, V. Boccone, D. Bosnar, M. Brugger, M. Calviani, F. Calviño, D. Cano-Ott, C. Carrapiço, F. Cerutti, E. Chiaveri,M. Chin, N. Colonna, G. Cortés, M. A. Cortés-Giraldo, M. Diakaki, C. Domingo-Pardo, N. Dzysiuk, C. Eleftheriadis, A. Ferrari, K. Fraval, S. Ganesan, A. R. García, G. Giubrone, M. B. Gómez-Hornillos, I. F. Gonçalves, E. González-Romero,E. Griesmayer, C. Guerrero, F. Gunsing, P. Gurusamy, D. G. Jenkins, E. Jericha, Y. Kadi, F. Käppeler,† D. Karadimos, P. Koehler, M. Kokkoris, M. Krticka, J. Kroll, C. Langer, C. Lederer, H. Leeb, R. Losito, A. Manousos, J. Marganiec, T. Martínez, C. Massimi, P. F. Mastinu,M. Mastromarco, M. Meaze, E. Mendoza, A. Mengoni, P. M. Milazzo, F. Mingrone, M. Mirea,,† W. Mondalaers, A. Pavlik, J. Perkowski, A. Plompen, J. Praena, J. M. Quesada, T. Rauscher, R. Reifarth, A. Riego, M. S. Robles, F. Roman, C. Rubbia, R. Sarmento, P. Schillebeeckx,S. Schmidt, G. Tagliente, J. L. Tain, A. Tsinganis, S. Valenta, G. Vannini, V. Variale, P. Vaz, R. Versaci, M. J. Vermeulen, V. Vlachoudis, R. Vlastou,A. Wallner, T. Ware, M. Weigand, C. Weiß, T. J. Wright, P. ŽugecPostprint (published version

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

Correction to: Cluster identification, selection, and description in Cluster randomized crossover trials: the PREP-IT trials

An amendment to this paper has been published and can be accessed via the original article

ESX-1-Independent Horizontal Gene Transfer by Mycobacterium tuberculosis Complex Strains

International audienceData on the bacterial sex-mediated impact on mycobacterial evolution are limited. Hence, our results presented here are of importance as they clearly demonstrate the capacity of a wide range of human- and animal-adapted Mycobacterium tuberculosis complex (MTBC) strains to transfer chromosomal DNA to selected strains of Mycobacterium canettii

Non-clinical assessment of lubrication and free radical scavenging of an innovative non-animal carboxymethyl chitosan biomaterial for viscosupplementation: An in-vitro and ex-vivo study.

Lubrication and free radical scavenging are key features of biomaterials used for viscosupplementation (VS) of joints affected by osteoarthritis (OA). The objective of this study was to describe the non-clinical performance characterization of KiOmedine® CM-Chitosan, a non-animal carboxymethyl chitosan, in order to assess its intended action in VS and to compare it to existing viscosupplements based on crosslinked hyaluronan (HA) formulations.info:eu-repo/semantics/publishe